These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12064991)

  • 21. Lack of adverse interactions between concomitantly administered selegiline and citalopram.
    Laine K; Anttila M; Heinonen E; Helminen A; Huupponen R; Mäki-Ikola O; Reinikainen K; Scheinin M
    Clin Neuropharmacol; 1997 Oct; 20(5):419-33. PubMed ID: 9331518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters.
    Ravna AW; Sylte I; Dahl SG
    J Pharmacol Exp Ther; 2003 Oct; 307(1):34-41. PubMed ID: 12944499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonergic/glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram.
    Winter JC; Eckler JR; Rice KC; Rabin RA
    Pharmacol Biochem Behav; 2005 Jul; 81(3):694-700. PubMed ID: 15970314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Citalopram in the treatment of depression and other potential uses in psychiatry.
    Tan JY; Levin GM
    Pharmacotherapy; 1999 Jun; 19(6):675-89. PubMed ID: 10391413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of combined treatment with noradrenaline and serotonin reuptake inhibitors on conditioned freezing.
    Inoue T; Nakagawa S; Izumi T; Kitaichi Y; Koyama T
    Eur J Pharmacol; 2006 Jul; 540(1-3):91-5. PubMed ID: 16714013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
    Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors.
    Dekeyne A; Denorme B; Monneyron S; Millan MJ
    Neuropharmacology; 2000 Apr; 39(6):1114-7. PubMed ID: 10727723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of the co-administration of the α₁-adrenoreceptor antagonist prazosin on the anxiolytic effect of citalopram in conditioned fear stress in the rat.
    Takamura N; Masuda T; Inoue T; Nakagawa S; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):107-11. PubMed ID: 22658980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography.
    Smith GS; Ma Y; Dhawan V; Chaly T; Eidelberg D
    Synapse; 2009 Jan; 63(1):1-6. PubMed ID: 18925655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment.
    Moeller O; Hetzel G; Rothermundt M; Michael N; Nyhuis PW; Suslow T; Arolt V; Erfurth A
    J Psychiatr Res; 2003; 37(3):261-2. PubMed ID: 12650745
    [No Abstract]   [Full Text] [Related]  

  • 31. Citalopram concentrations in samples from autopsies and living persons.
    Worm K; Dragsholt C; Simonsen K; Kringsholm B
    Int J Legal Med; 1998; 111(4):188-90. PubMed ID: 9646161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-methyl-citalopram: A quaternary selective serotonin reuptake inhibitor.
    Bismuth-Evenzal Y; Roz N; Gurwitz D; Rehavi M
    Biochem Pharmacol; 2010 Nov; 80(10):1546-52. PubMed ID: 20696140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Citalopram: another SSRI antidepressant.
    Price PL
    S D J Med; 1999 Mar; 52(3):99-100. PubMed ID: 10100452
    [No Abstract]   [Full Text] [Related]  

  • 34. Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.
    Millan MJ; Veiga S; Girardon S; Brocco M
    Psychopharmacology (Berl); 2003 Aug; 168(4):397-409. PubMed ID: 12721776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacogenetics of the selective serotonin reuptake inhibitors.
    Brøsen K
    Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor.
    Izumi T; Inoue T; Kitaichi Y; Nakagawa S; Koyama T
    Eur J Pharmacol; 2006 Mar; 534(1-3):129-32. PubMed ID: 16494863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Citalopram for verbal agitation in patients with dementia.
    Kim KY; Bader GM; Jones E
    J Geriatr Psychiatry Neurol; 2000; 13(2):53-5. PubMed ID: 10912724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Citalopram--a review of pharmacological and clinical effects.
    Bezchlibnyk-Butler K; Aleksic I; Kennedy SH
    J Psychiatry Neurosci; 2000 May; 25(3):241-54. PubMed ID: 10863884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 5-HT(2C) receptor-mediated interaction between 2,5-dimethoxy-4-methylamphetamine and citalopram in the rat.
    Eckler JR; Reissig CJ; Rabin RA; Winter JC
    Pharmacol Biochem Behav; 2004 Sep; 79(1):25-30. PubMed ID: 15388280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiation of DOM-induced stimulus control by fluoxetine and citalopram: role of pharmacokinetics.
    Eckler JR; Doat MM; Rabin RA; Winter JC
    Life Sci; 2002 Aug; 71(11):1341-7. PubMed ID: 12106599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.